Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

Company Overview - Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline for nicotine dependence and smoking cessation [3] - The company has completed two Phase 3 studies and one Phase 2 study related to cytisinicline, with plans to submit a new drug application in June 2025 [3] Product Information - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors in the brain, aimed at reducing nicotine cravings and the satisfaction derived from nicotine products [5] - The product has received Breakthrough Therapy designation from the FDA, highlighting its potential to address the significant need for effective smoking and vaping cessation treatments [4][5] Market Context - Approximately 29 million adults in the U.S. smoke combustible cigarettes, with tobacco use being the leading cause of preventable death globally [4] - There are over 11 million adults in the U.S. who use e-cigarettes, and no FDA-approved treatments specifically for e-cigarette cessation currently exist [4] Upcoming Events - Achieve Life Sciences will report its first quarter 2025 financial results and provide updates on the cytisinicline development program on May 13, 2025, at 8:30 AM EDT [1]